Valore202020212022202320242025TTMSpese di vendita, generali e amministrative303.3 M348.4 M340.3 M368.4 M308 M186.1 M186.1 MRicerca e sviluppo234.5 M234 M193 M111.4 M70.7 M53.2 M53.2 MReddito operativo433.8 M352.6 M172.7 M726.4 M108.7 M100.1 M100.1 MProventi non operativi, Totale26.6 M38.2 M49 M4.8 M34.2 M17.3 M17.3 MOneri finanziari, al netto degli interessi capitalizzati31.3 M34.5 M37.3 M87.9 M71 M59.3 M59.3 MProventi non operativi, esclusi gli oneri finanziari-9.4 M00-92 M-49.3 M-96.2 M-96.2 MEntrate/uscite straordinarie4.7 M3.7 M11.7 M8.9 M12.5 M54.2 M54.2 MUtile al lordo delle imposte407.2 M314.4 M221.7 M731.2 M142.9 M82.8 M82.8 MQuota di utile———————Imposte102.1 M83.5 M2.1 M29.3 M47.7 M30.2 M30.2 MInteressi di minoranza———————Altri proventi/oneri al netto delle imposte5.2 M2 M6.4 M13 M6.5 M400 K400 KUtile netto al lordo delle attività cessate305.1 M230.9 M223.8 M760.5 M190.6 M52.6 M28.6 MAttività cessate———————Utile netto305.1 M230.9 M223.8 M760.5 M190.6 M52.6 M28.6 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari305.1 M230.9 M223.8 M760.5 M190.6 M52.6 M28.6 MUtile base per azione (EPS base)5.794.32-4.47-14.85-3.60.980.98Utile diluito per azione (EPS diluito)5.674.27-4.47-14.85-3.60.930.93Numero medio di azioni ordinarie in circolazione52.7 M53.5 M50.1 M51.2 M53 M53.5 M216.1 MAzioni diluite in circolazione53.8 M54.1 M50.1 M51.2 M53 M56.7 M227.4 MEBITDA-343.4 M258.4 M-910.4 M-1.6 B-341.9 M-320.9 M-320.9 MEBIT-393.5 M4.2 M-1.21 B-1.73 B-393.3 M-407.7 M-407.7 MCosto del fatturato524 M—693.7 M705.4 M—326.2 M326.2 MAltri costi del venduto———————Ammortamento e svalutazione (liquidità)50.1 M254.2 M296.3 M125.1 M108.8 M95.8 M95.8 M
Emergent BioSolutions Inc
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.